Tag: licensing
-
Blood Stem Cell Start-Up Launches, Earns $48.5M Funding
A new enterprise, spun-off from Harvard University stem cell labs, aims to make stem cell transplants from bone marrow safer and more reliable.
-
Laser-Immunotherapy Now in Cancer Clinical Trial
A new type of cancer treatment that precisely attacks tumors with synthetic antibodies activated by laser beams is being tested in an early-stage clinical trial.
-
Long-Acting Opioid Abuse Therapy Shown Working in Trial
An experimental long-acting drug was shown at least as effective, and in some cases superior, to the current standard of care for opioid use disorder.
-
Clinic Opens for Engineered T-Cell Cancer Therapies
A clinic to provide cancer treatments that use a patient’s immune system cells engineered to fight cancer is open at the Fred Hutchinson Cancer Research Center in Seattle.
-
Biotech, Univ of Miami Spin-Off Vaccine Company
Biotechnology company Heat Biologics Inc. is licensing research from University of Miami in Florida to develop vaccines against infectious diseases, starting with the Zika virus, in a new subsidiary.
-
Gene Silencing Treatments Licensed for Heart Disease
Biopharmaceutical company Amgen is acquiring the rights to a technology that stops the actions of inherited genes associated with a leading type of heart disease.
-
Harvard Spin-Off to Sequence, Visualize RNA in Tissue
A new spin-off enterprise from Harvard University is commercializing technology that enables sequencing and imaging of genetic transcriptions of cells in their original tissue.
-
Spin-Off Companies to Develop Chronic Disease Therapies
Two new spin-off enterprises are being created to develop gut-based treatments for chronic diseases using technologies from synthetic biology company Intrexon Corporation.
-
Monsanto Licensing MIT/Harvard Genome Editing
Monsanto Company is licensing genomic editing technology for agricultural applications from a joint research center at Harvard University and MIT.
-
Genentech, BioNTech Partner on Personal Cancer Therapies
Biotechnology company BioNTech AG is licensing its messenger RNA technology and collaborating with biopharmaceutical company Genentech to develop personalized cancer immunotherapies.